ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at the Proactive London studio after confirming to the market that the specialty biopharmaceutical will be moving forward into a key phase 2/3 adaptive clinical trial, alongside its US partners Avion Pharmaceuticals. McCarthy says that he's "absolutely delighted" to be moving forward with the study and emphasises the significant potential of its deal with Avion, including milestone payments of up to $70 million and double-digit royalty percentages, in addition to obvious benefit to patients. McCarthy also mentions ongoing discussions for more commercial partnerships and the potential for major breakthroughs in the future.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
